1,334
Views
8
CrossRef citations to date
0
Altmetric
Drug Evaluation

Breakthrough therapy designation of nirsevimab for the prevention of lower respiratory tract illness caused by respiratory syncytial virus infections (RSV)

ORCID Icon & ORCID Icon
Pages 23-29 | Received 10 Sep 2021, Accepted 15 Dec 2021, Published online: 28 Dec 2021

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (2)

Catherine Weil-Olivier, David Salisbury, José Antonio Navarro-Alonso, Chryssoula Tzialla, Yan Zhang, Susanna Esposito, Fabio Midulla & Tobias Tenenbaum. (2023) Immunization technologies: Time to consider new preventative solutions for respiratory syncytial virus infections. Human Vaccines & Immunotherapeutics 19:1.
Read now
Eugenio Baraldi, Giovanni Checcucci Lisi, Claudio Costantino, Jon H. Heinrichs, Paolo Manzoni, Matteo Riccò, Michelle Roberts & Natalya Vassilouthis. (2022) RSV disease in infants and young children: Can we see a brighter future?. Human Vaccines & Immunotherapeutics 18:4.
Read now

Articles from other publishers (6)

Shiza Malik, Tahir Ahmad, Khalid Muhammad & Yasir Waheed. (2023) Respiratory Syncytial Virus Infection: Treatments and Clinical Management. Vaccines 11:2, pages 491.
Crossref
Matteo Riccò, Silvia Corrado, Milena Pia Cerviere, Silvia Ranzieri & Federico Marchesi. (2023) Respiratory Syncytial Virus Prevention through Monoclonal Antibodies: A Cross-Sectional Study on Knowledge, Attitudes, and Practices of Italian Pediatricians. Pediatric Reports 15:1, pages 154-174.
Crossref
Matteo Riccò, Milena Pia Cerviere, Silvia Corrado, Silvia Ranzieri & Federico Marchesi. (2022) Respiratory Syncytial Virus: An Uncommon Cause of Febrile Seizures—Results from a Systematic Review and Meta-Analysis. Pediatric Reports 14:4, pages 464-478.
Crossref
Jessica Hartnett, Prina Donga, Gabriela Ispas, Yannick Vandendijck, David Anderson, Stacey House & Selim Suner. (2022) Risk factors and medical resource utilization in US adults hospitalized with influenza or respiratory syncytial virus in the Hospitalized Acute Respiratory Tract Infection study. Influenza and Other Respiratory Viruses 16:5, pages 906-915.
Crossref
Oludare A Odumade, Simon D van Haren & Asimenia Angelidou. (2022) Implications of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Pandemic on the Epidemiology of Pediatric Respiratory Syncytial Virus Infection. Clinical Infectious Diseases 75:Supplement_1, pages S130-S135.
Crossref
William R. Strohl, Zhiqiang Ku, Zhiqiang An, Stephen F. Carroll, Bruce A. Keyt & Lila M. Strohl. (2022) Passive Immunotherapy Against SARS-CoV-2: From Plasma-Based Therapy to Single Potent Antibodies in the Race to Stay Ahead of the Variants. BioDrugs 36:3, pages 231-323.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.